Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey

• Oguma Tsuyoshi

  Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine

• Taniguchi Masami

  Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital

• Shimoda Terufumi

  Clinical Research Center, Fukuoka National Hospital

• Kamei Katsuhiko

  Division of Clinical Research, Medical Mycology Research Center, Chiba University

• Matsuse Hiroto

  Division of Respirology, Department of Internal Medicine, Toho University Ohashi Medical Center

• Hebisawa Akira

  Clinical Research Center, Tokyo National Hospital

• Takayanagi Noboru

  Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center

• Konno Satoshi

  First Department of Medicine, Hokkaido University Graduate School of Medicine

• Fukunaga Koichi

  Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine

• Harada Kazuki

  Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine

• Tanaka Jun

  Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine

• Tomomatsu Katsuyoshi

  Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine

• Asano Koichiro

  Division of Pulmonary Medicine, Department of Medicine, Tokai University School of Medicine

Abstract

Background: Allergic bronchopulmonary aspergillosis (ABPA) is an allergic pulmonary disease characterized by a hypersensitivity reaction to Aspergillus species colonizing the airways. The clinical characteristics of ABPA may differ depending on genetic and environmental background. We performed a nationwide survey to determine the clinical characteristics of ABPA in Japan. Methods: In 2013, a questionnaire on physician-diagnosed ABPA/allergic bronchopulmonary mycosis was sent to 903 medical centers specializing in respiratory or allergic diseases. Cases fulfilling the following criteria were categorized as possible ABPA-central bronchiectasis (ABPA-CB): 1) presence of specific serum immunoglobulin E (IgE) antibodies or a positive skin reaction to Aspergillus, and 2) bronchiectasis or mucoid impaction in the central bronchi. Results: Of 499 physician-diagnosed cases reported by 132 clinical centers, 358 cases met the criteria for possible ABPA-CB. Median age of ABPA-CB onset was 57 (interquartile range, 44-68) years; later-onset disease, developing ≥50 years of age, accounted for 66% of the cases and was associated with female sex, delayed onset of asthma, and lower levels of serum IgE. A third of the patients (120 patients, 34%) exhibited low levels of serum total IgE (<1000 IU/mL). Aspergillus species were isolated from sputum in 126/213 cases (59%), and Schizophyllum commune was identified in 12 (6%) patients. During the course of the treatment, ABPA recurred in 169 (48%) cases. Conclusions: This nationwide survey identified several unique clinical characteristics of ABPA in Japan, such as late-onset, relatively lower serum IgE levels, and frequent recurrences/flares.

Journal

• Allergology International

  Allergology International 67 (1), 79-84, 2018

  Japanese Society of Allergology

Keywords

• Allergic bronchopulmonary aspergillosis
• <i>Aspergillus</i>
• Bronchiectasis
• Immunoglobulin E
• <i>Schizophyllum commune</i>

Details

• CRID: 1390001204632841344
• NII Article ID: 130006322061
• DOI: 10.1016/j.alit.2017.04.011
• ISSN: 14401592
• ISSN: 13238930
• Web Site: https://api.elsevier.com/content/article/PII:S1323893017300527?httpAccept=text/xml
• Web Site: https://api.elsevier.com/content/article/PII:S1323893017300527?httpAccept=text/plain
• Web Site: https://search.jamas.or.jp/link/ui/2019170473
• Text Lang: en
• Data Source:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• Abstract License Flag: Disallowed